CLD-101, a stem cell-based platform, delivers oncolytic viruses to tumors, targeting high-grade glioma in a phase 1b/2 trial. Previous trials demonstrated CLD-101's safety and potential efficacy, with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback